



173 Enhancement of the functional benefits of skeletal myoblast transplantation
by means of coadministration of hypoxia-inducible factor 1
Kasra Azarnoush, MD, Agnès Maurel, PhD, Laurent Sebbah, MD, Claire Carrion,
Alvine Bissery, MSc, Chantal Mandet, Julia Pouly, MD, Patrick Bruneval, MD,
Albert A. Hagège, MD, PhD, and Philippe Menasché, MD, PhD, Paris, France
In a rat model of myocardial infarction, the coinjection of skeletal myoblasts and the
transcription factor hypoxia-inducible factor 1 resulted in a superior preservation of left
ventricular function, which correlated with a greater degree of angiogenesis, myogenic cell
engraftment, and overall cell survival compared with myoblast transplantation alone.
180 Evaluation of the oxygenation ratio in the definition of early graft
dysfunction after lung transplantation
Takahiro Oto, MD, Bronwyn J. Levvey, RN, David V. Pilcher, MRCP,
Michael J. Bailey, MSc (statistics), and Gregory I. Snell, FRACP, Melbourne, Victoria, Australia
The prevalence of PaO2/FIO2 less than 200 decreased in the range from 44% at 0 hours to 8% at
12 hours. Early outcomes (duration of intubation, length of ICU stay, and 30-day mortality)
best correlate with PaO2/FIO2 6 to 12 hours after lung transplantation.
187 Does duration of donor brain injury affect outcome after orthotopic
pediatric heart transplantation?
Jonah Odim, MD, PhD, MBA, Hillel Laks, MD, Anamika Banerji, MS, Kaushik Mukherjee, BS,
Chris Vincent, MD, Charles Murphy, MD, Caron Burch, RN, MSN, and David Gjertson, PhD,
Los Angeles, Calif
In a study of 93 cardiac transplants performed at a single center, longer brain injury and death
intervals correlated with improved freedom from rejection but had no effect on recipient
mortality.
194 Inhibition of nuclear factor B by IB superrepressor gene transfer
ameliorates ischemia-reperfusion injury after experimental lung
transplantation
Takaaki Ishiyama, MD, Sekhar Dharmarajan, MD, Makio Hayama, MD, Hisao Moriya, PhD,
Kathleen Grapperhaus, BSc, and G. Alexander Patterson, MD, FRCS(C), St Louis, Mo
NFB is a transcription factor central to the pathogenesis of acute lung injury. We demonstrate
that inhibition of NFB activation with gene therapy significantly improves isolated lung graft
oxygenation, decreases pulmonary edema and neutrophil sequestration, and reduces apoptotic
cell death in ischemia-reperfusion injury after experimental lung transplantation.
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